03/30/2026 ValuEngine Weekly Market Summary & Commentary

Weekly Market Recap – Week Ending March 27, 2026 U.S. equity markets experienced broad-based weakness this week, with growth-oriented and technology-heavy segments leading the decline, as reflected in notable pullbacks across major ETFs such as QQQM, XLK, and XLC. Despite this overall softness, pockets of strength emerged in energy and materials, where rising commodity prices … Read more

02/02/2026 ValuEngine Weekly Market Summary & Commentary

Weekly Market Recap – Week Ending January 30, 2026 Equity markets finished the week with a mixed tone as leadership continued to rotate across sectors and styles. While large-cap growth and technology-oriented exposures showed modest weakness, select income and defensive segments posted gains, underscoring an environment driven more by rotation than broad market momentum. Energy … Read more

12/30/2025 ValuEngine Weekly Market Summary & Commentary

December 29 – Santa Rally Continues but Gold Still Rules Happy Holidays from everyone at ValuEngine!  Due to the holidays and vacation schedules this week’s Market Summary and Commentary will be brief and missing the ETF and stock performance tables. All will resume as normal next week. Here is the strategy note for this week: … Read more

12/1/2025 ValuEngine Weekly Market Summary & Commentary

Weekly Market Recap – Week Ending November 28, 2025 Market action during Thanksgiving week delivered a broad-based rebound across U.S. equities. Nearly every ETF in our coverage list finished higher, led by strong gains in small caps (VB +3.64%), consumer discretionary (XLY +3.48%), and materials (XLB +3.33%). Large-cap growth also participated, with QQQM rising 2.31% … Read more

10/06/2025 ValuEngine Weekly Market Summary & Commentary

Weekly Market Recap – Week Ending October 03, 2025 Markets ended the week on a broadly positive note, closing out the third quarter with strength in technology, healthcare, and small caps. Despite mixed performance across sectors, investor sentiment remained resilient ahead of the start of Q4 earnings season. Free Trial: Research on over 5,000 stocks … Read more